Dynamic contrast-enhanced MRI enables measurements of the permeability of the blood-brain barrier (BBB), possibly a marker of disease activity in multiple sclerosis (MS). In order to investigate if permeability predicts early suboptimal treatment response, defined as loss of no evidence of disease activity (NEDA) status after two years, we included 35 relapsing-remitting MS patients initiating either fingolimod or natalizumab, drugs with a common effect of decreasing lymphocyte influx into the CNS. We find that permeability measured after six months of treatment was a good predictor loss of NEDA status at two years and a surrogate marker of the state of health of the blood-brain barrier.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords